Form 4: Lyell Immunopharma Director Receives Stock Option Grant

Director Elizabeth G. Nabel was granted 9,250 stock options in Lyell Immunopharma, Inc. as part of standard compensation.

Summary

• Director Elizabeth G. Nabel received a grant of 9,250 stock options for Lyell Immunopharma, Inc. (LYEL) common stock.
• The options have an exercise price of $13.22 per share.
• The grant date is June 10, 2025, with an expiration date of June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The exercise price of $13.22 represents a significant premium over recent market trading prices, suggesting the options are currently out-of-the-money.

Risks

• Potential dilution of existing shareholders upon the eventual exercise of these options.
• Market volatility affecting the value of equity-based compensation.

Future Outlook

The options vest on the earlier of the next annual meeting following June 10, 2026, or the first anniversary of that date, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though the high exercise price relative to current market conditions reflects the company's long-term growth expectations.

Comparison to Industry Standards

• The grant structure follows standard industry practices for board compensation in clinical-stage biopharmaceutical companies.
• Vesting schedules tied to annual meetings are consistent with corporate governance norms for independent directors.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options scheduled for June 2026 or the subsequent annual meeting.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Director Compensation, Stock Options, Insider Transaction, Biotech